

# ESTRO2025

## Call for Papers

### ***Green Journal and The Lancet Oncology* collaboration**

*Radiotherapy & Oncology* and the European Society for Radiotherapy and Oncology (ESTRO) are delighted to announce that we will be entering a collaboration with *The Lancet Oncology* to co-host a research session dedicated to clinical trials in radiation oncology at the 2025 ESTRO congress in Vienna, Austria, 2–6 May 2025. Our aim is to publish the best trials submitted to the congress to coincide with their presentation in a dedicated clinical trials session. We are particularly interested in high-quality trials that have the potential to change clinical practice or current thinking in radiation oncology.

For your trial to be considered for this session and for potential coordinated publication in either *Radiotherapy & Oncology* or *The Lancet Oncology*, please first submit an abstract for consideration at the ESTRO 2025 congress via the conference website by 20 November 2024. Abstract submission for the ESTRO 2025 congress will open on 2 September 2024. Authors of abstracts accepted for presentation at the congress will be notified by 5 February 2025. The editors of *Radiotherapy & Oncology* and *The Lancet Oncology* will be involved in the screening and selection process, and authors of abstracts considered of interest to either journal will be invited to submit their full article to one of the journals in the notification email that confirms acceptance of their abstract at the congress.

For those authors invited to submit articles, the complete manuscripts must be submitted to the relevant journal by 10 February 2025. Only articles accepted for publication in either journal will be eligible for possible inclusion in the clinical trials session at the ESTRO 2025 congress. A decision to not publish an invited article in either journal will not affect acceptance of the abstract at the congress. All decisions on invited articles will be made on the basis of full editorial assessment and peer review according to the journal's procedures.

We look forward to this exciting collaboration and to seeing you in Vienna in 2025.

*Pierre Blanchard and David Collingridge*

Pierre Blanchard is the Editor-in-Chief of *Radiotherapy & Oncology* and David Collingridge is the Editor-in-Chief of *The Lancet Oncology*.

Department of Radiation Oncology, Gustave Roussy, Université Paris-Saclay, 94800 Villejuif, France (PB); *The Lancet Oncology*, 125 London Wall, London EC2Y 5AS, UK (DC)